Imaging the inflammatory response with PET could provide more information about traumatic brain injury (TBI) than conventional CT and MRI methods, according to preliminary research presented during the Military Health System Research Symposium held in Ft. Lauderdale, Fla., Aug. 12. {read more here}

GE Healthcare announced that its PET imaging agent for Alzheimer’s has been approved for market by the U.S. Food and Drug Administration. Vizamyl (flutemetamol F 18 injection) is used to visually detect beta amyloid plaque, which is associated with Alzheimer’s and dementia, in the brains of patients being evaluated for the conditions.  {read more here}

Delayed brain injury resulting from aggressive radiation treatment can be differentiated from recurrent brain tumors using F-18 FDOPA PET imaging, according to a study published Oct. 28 in the Journal of Nuclear Medicine. {read more here}

A comparatively new tool in the fight against childhood brain cancer has been shown enhance conventional magnetic resonance imaging (MRI) technology by providing information about tumor metabolism and the level of cancer in children diagnosed with glioma, a growth caused by the abnormal division of glial cells in the brain. {read more here}